Redeye initiates coverage of Corline Biomedical, a Swedish medtech/biotech company specialising in c...
Medical has stabilised following a period of volatile margins More margin expansion left, Medical to...
Consti reports its Q4 result on 7th of February. We anticipate slight sales growth for Q4, although ...
LapWall releases its Q4 result on 6th of February. As the 2024 result is already largely known, our ...
NanoEcho är ett medicintekniskt bolag som utvecklar ett innovativt bildgivande system för tydligare ...
Q4 markerar en sval avslutning på året och Coor har flaggat för pressade marginaler mot bakgrund av ...
Redeye updates its estimates and valuation on Embracer to reflect the Asmodee spin-off and the stron...
Redeye has revised its near-term estimates and valuation following the Q4 report, which showed resil...
Redeye updates its estimates and valuation following Lifco releasing its Q4 2024 report.
Minor positive estimate revisions Margin expansion to be increasingly driven by scale Trading at '25...
Redeye comments on today’s news that the European Commission has asked EMA’s CHMP to consider two ad...
Redeye publish a preview ahead of Northbaze's Q4 results, set to be released on Februaty 20.
Q4: -6% org. sales growth, 2% adj. EBITA growth, strong cash flow '25e-'26e adj.
Redeye provides its initial take on Lifco’s Q4 2024 report, which featured a slight sales beat and m...
Redeye comments on WntResearch’s conditional reverse acquisition of OPSY AB.
